Suppr超能文献

长期给予Rho激酶抑制剂可改善恶性高血压大鼠的肾损伤。

Long-term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats.

作者信息

Ishikawa Yayoi, Nishikimi Toshio, Akimoto Kazumi, Ishimura Kimihiko, Ono Hidehiko, Matsuoka Hiroaki

机构信息

Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi, Japan.

出版信息

Hypertension. 2006 Jun;47(6):1075-83. doi: 10.1161/01.HYP.0000221605.94532.71. Epub 2006 Apr 24.

Abstract

We have shown recently that fasudil, a Rho-kinase inhibitor, has renoprotective effects in salt-sensitive hypertensive rats. We hypothesized that activation of Rho-kinase is involved in the pathogenesis of glomerulosclerosis in malignant hypertensive rats. To test this hypothesis, we studied the following 4 groups: control Wistar-Kyoto rats, untreated deoxycorticosterone-acetate salt spontaneously hypertensive rats (DOCA-SHR), low-dose fasudil-treated DOCA-SHR, and high-dose fasudil-treated DOCA-SHR. After 3 weeks of treatment, the effects of fasudil were examined. DOCA-SHR was characterized by increased blood pressure (BP); increased kidney weight; decreased renal function; increased proteinuria; abnormal histological findings; increased monocyte/macrophage infiltration; increased urinary 8-isoprostran levels; increased gene expression of collagen I, collagen III, transforming growth factor-beta, and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits (p40phox, p47phox, and p67phox); and decreased gene expression of endothelial NO synthase (eNOS) in the renal cortex as compared with Wistar-Kyoto rats. Long-term high-dose fasudil treatment significantly improved renal function and histological findings without changing BP, as compared with untreated DOCA-SHR. Interestingly, long-term fasudil treatment significantly decreased monocyte/macrophage infiltration and urinary 8-isoprostran excretion, in association with decreased mRNA levels of transforming growth factor-beta, collagen I, collagen III, and NADPH oxidase subunits (p40phox, p47phox, and p67phox), and increased mRNA levels of eNOS in the renal cortex. Long-term low-dose fasudil treatment tended to improve these variables slightly but did not affect most of them significantly. Our results suggest that long-term fasudil treatment provides renoprotective effects independent of BP-lowering activity. These renoprotective effects are associated with inhibition of extracellular matrix gene expression, monocyte/macrophage infiltration, oxidative stress, and upregulation of eNOS gene expression.

摘要

我们最近发现,Rho激酶抑制剂法舒地尔对盐敏感性高血压大鼠具有肾脏保护作用。我们推测,Rho激酶的激活参与了恶性高血压大鼠肾小球硬化的发病机制。为了验证这一假设,我们研究了以下4组:对照Wistar-Kyoto大鼠、未治疗的醋酸脱氧皮质酮盐自发性高血压大鼠(DOCA-SHR)、低剂量法舒地尔治疗的DOCA-SHR和高剂量法舒地尔治疗的DOCA-SHR。治疗3周后,检测法舒地尔的效果。DOCA-SHR的特征为血压(BP)升高;肾脏重量增加;肾功能下降;蛋白尿增加;组织学检查结果异常;单核细胞/巨噬细胞浸润增加;尿8-异前列腺素水平升高;I型胶原、III型胶原、转化生长因子-β和还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶亚基(p40phox、p47phox和p67phox)的基因表达增加;与Wistar-Kyoto大鼠相比,肾皮质中内皮型一氧化氮合酶(eNOS)的基因表达下降。与未治疗的DOCA-SHR相比,长期高剂量法舒地尔治疗可显著改善肾功能和组织学检查结果,而血压不变。有趣的是,长期法舒地尔治疗可显著减少单核细胞/巨噬细胞浸润和尿8-异前列腺素排泄,同时肾皮质中转化生长因子-β、I型胶原、III型胶原和NADPH氧化酶亚基(p40phox、p47phox和p67phox)的mRNA水平下降,eNOS的mRNA水平升高。长期低剂量法舒地尔治疗倾向于轻微改善这些变量,但对大多数变量没有显著影响。我们的结果表明,长期法舒地尔治疗可提供独立于降压活性的肾脏保护作用。这些肾脏保护作用与细胞外基质基因表达的抑制、单核细胞/巨噬细胞浸润、氧化应激以及eNOS基因表达的上调有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验